Research in Context
Introduction
Alzheimer's disease (AD) currently affects roughly 5.7 million people in the United States [1] . By 2025, it is expected that 7.1 million people will be affected [1] , highlighting the urgency for progress in AD-focused research. AD is highly heritable, with as much as 79% shared heritable risk reported in twin studies [2] , although the genetic architecture is complex including notable polygenicity. Phenotypically, AD includes a long prodrome in which neuropathology begins to accumulate decades before cognitive symptoms can be detected [3, 4] . For that reason, early detection is critical to prevent progression of the disease [5, 6] . A combined screening approach that integrates biomarker, genomic, and clinical information will likely be required to optimize early identification and prevention of AD progression [7, 8] .
Polygenic risk scores (PRS) represent a tool for early AD risk detection; however, studies that used PRS to predict AD case/control status reported predictive accuracy (AUCmax) of less than 83% [9] [10] [11] [12] , and the clinical utility of PRS beyond the APOE locus have been questioned [12, 13] . A wealth of genetic data from genome-wide association studies (GWAS) have become available in recent years [14] , and incorporation of additional genetic data may represent a strategy to improve PRS predictive ability. In 2010, the largest GWAS of AD involved ~16,000 participants [15] , compared to the recently completed AD GWAS that included ~600,000 participants [16] . This increase in GWAS data have enabled an increase in the number of single nucleotide polymorphisms (SNPs) used to calculate AD genetic risk scores. Some of the first PRS studies used as few as 5 SNPs to calculate AD risk, compared to 205,068
SNPs in a more recent study [17] . Despite the progress made in genomic studies of AD, PRS continue to show limited power, and innovative analytical strategies from novel perspectives are required if PRS are going to attain clinical utility. Improvement for PRS may come from GWAS of AD endophenotypes which focus on neuropathological features of the disease. In fact, in vivo biomarkers of AD neuropathology have become a central feature used to identify cognitively normal individuals who are at the greatest risk of cognitive decline [4, 18] . Additionally, the National Institute on Aging and Alzheimer's Association released a research framework for AD in which the pathological accumulation of amyloid plaques (A), neurofibrillary tangles composed of tau (T), and neurodegeneration (N) are recommended to be included in diagnostic categories of AD used for research [19] . While this A/T/N framework has emerged in studies of preclinical disease, it has not been integrated into PRS for AD despite the availability of GWAS summary statistics for autopsy and in vivo measures of A/T/N [20, 21] . Indeed, a previous study suggested that shared genetic drivers for hippocampal volume (a marker of neurodegeneration) and AD may exist [22] . Thus, integrating the common and independent genetic drivers of clinical AD and A/T/N could produce models with higher predictive capacity for cognitive decline in late life.
We set out to determine how PRS for CSF biomarkers of AD (amyloid and ptau181), hippocampal volume, and clinical AD relate to biomarkers of AD and longitudinal cognitive performance. We then developed a novel composite PRS using the A/T/N framework to integrate genetic risk for AD biomarkers, hippocampal volume, and clinical AD diagnosis into a single score (A/T/N PRS). We compared the predictive capabilities of the A/T/N score to a PRS score for clinical AD and hypothesized that the A/T/N PRS would serve as a more predictive genetic risk profile compared to a PRS for clinical AD alone.
Methods

Participants
Participants were drawn from the Alzheimer's Disease Neuroimaging Initiative database (ADNI; adni.loni.usc.edu) launched in 2003 as a public-private partnership. The ADNI, ADNI-GO and ADNI-2 studies enrolled more than 1,500 participants, aged 55-90 years, excluding serious neurological disease, other than AD, and history of brain lesion, head trauma, or psychoactive medication use (for full inclusion/exclusion criteria see http://www.adni-info.org). Written informed consent was obtained from all participants at each site, and analysis of ADNI's publicly available database was approved by our local Institutional Review Board prior to data analysis.
We accessed publicly available participant data from ADNI on July 12, 2018. ADNI enrollment criteria are outlined in the ADNI protocol (http://www.adniinfo.org/Scientists/AboutADNI.aspx). For the cognitive analyses, we included all participants who had genomic data and longitudinal cognitive (memory and executive function) data, yielding a sample size of 1,181 participants. From this sample, 1,086 subjects also had brain MRI data and were included in neuroimaging analyses. CSF biomarker data was available for 826 participants of those whom had genomic and cognitive data. Demographics of participants with genetic and cognitive data are shown in Table 1 .
CSF collection and assays for Aβ42 and ptau181
The ADNI protocol for CSF collection and quantification of Aβ42 and ptau181 biomarkers has been detailed previously, and used the multiplex xMAP Luminex platform [23, 24] . For this study, the UPenn master data set that was available on the ADNI website was downloaded. The first biomarker measurement for each participant was used as a continuous variable in statistical models.
Diagnostic criteria
Full details of these diagnostic criteria have been previously published [25] . Briefly, Normal Cognition (NC) participants had a Mini-Mental State Exam [26] (MMSE) score between 24-30 (inclusive), a Clinical Dementia Rating (CDR) of 0, and were non-depressed. Mild Cognitive Impairment (MCI) participants scored between 24-30 (inclusive) on the MMSE, had a memory complaint or objective memory loss as measured by the Wechsler Memory Scale-Revised (WMS-R) Logical Memory II, a CDR of 0.5, and absence of impairments significant enough to fit criteria for dementia. An AD diagnosis required MMSE scores between 20-26 (inclusive), a CDR score of 0.5-1.0 and meeting probable AD criteria [27] .
Brain Imaging
The ADNI neuroimaging protocol has been reported in detail elsewhere [28] . Images for the current study included original uncorrected 1.5T (ADNI-1) and 3.0T (ADNI-2, ADNI-GO) T1weighted high-resolution three-dimensional structural data. Cortical reconstruction and volumetric segmentation were performed with the FreeSurfer image analysis suite version 4.3 in ADNI-1 and 5.1 in ADNI-2 [29] [30] [31] (http://surfer.nmr.mgh.harvard.edu/). FreeSurfer processing in ADNI has been described in detail elsewhere [32] . FreeSurfer scans were assigned a quality control (QC) value of pass, fail or partial [33] . We excluded all scans that did not have a pass QC value. We used left hippocampal volume as our primary neuroimaging outcome measurement and included a measurement of intracranial volume (ICV) and scanner strength as covariates in all volumetric analyses, with volumetric measurements defined in FreeSurfer [34] .
Neuropsychological Testing
The ADNI neuropsychological protocol, including calculation of episodic memory and executive function composite measures, has been reported previously [35, 36] . Memory (ADNI-MEM) and executive function (ADNI-EF) composite scores were used for this study. ADNI-MEM included a composite z-score based on item-level data from Rey Auditory Verbal Learning Test,
Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Test, and Logical
Memory I and II. ADNI-EF included item-level data from Trail Making Test Parts A and B, Digit Symbol, Digit Span Backward, Animal Fluency, Vegetable Fluency, and Clock Drawing Test.
Genotyping and Genetic Quality Control Procedures
ADNI genotyping was performed using the Illumina Human610-Quad BeadChip (ADNI-1), the HumanOmniExpress BeadChip (ADNI-GO/2), or the Illumina Omni 2.5M WGS platform (Illumina, Inc., San Diego, CA). Quality control was performed using PLINK [37] (http://pngu.mgh.harvard.edu/purcell/plink) with a 95% threshold for genotyping efficiency applied and a minimum minor allele frequency of 0.01. SNPs outside of Hardy-Weinberg equilibrium (p<1x10 6 ) were removed. Participants were excluded if they had a call rate <99%, if there was an inconsistency between reported and genetic sex, or if relatedness to another sample was established (Pihat > 0.4), in which case one participant was selected to remain in the dataset at random (9 samples removed). Imputation was performed on the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html) using the HRC r1.1.2016 reference panel. Population structure was analyzed using the fastStructure software package [38] .
Polygenic Risk Score Calculation
We utilized data from a GWAS for CSF biomarkers published by Deming and colleagues [20] . The original data for this study was collected from 3,146 individuals across nine cohort studies, including ADNI. After removing ADNI participants [N=390 (ADNI-1), 397 (ADNI-2)], the GWAS was re-run using data from 2,359 participants in the remaining seven cohorts. Summary results of the re-analyses excluding ADNI participants are available in Supplementary Materials.
A GWAS for clinical AD using data from the International Genomics of Alzheimer's Project (IGAP) [39, 40] was re-run excluding 441 ADNI participants (55,931 participants Publicly available summary statistics from a UK Biobank GWAS of brain imaging phenotypes that included 8,428 participants [21] was utilized to generate ADNI participant PRS for left hippocampal volume.
PRS were calculated for each outcome in PLINK 1.9 using the scoring function (https://www.cog-genomics.org/plink/1.9/) based on summary statistics from overlapping SNPs in the ADNI cohort and the GWAS studies detailed above. The number of overlapping SNPs to calculate PRS are shown in Supplemental Table 1 . We calculated PRS scores using a linkage disequilibrium threshold of 0.25 and physical distance of 200kb for clumping to select independent SNPs. A significance threshold of 0.01 was used for index SNPs, with a secondary significance threshold of 0.5 for clumped SNPs. Scores were generated including and excluding the APOE region, defined as 1MB up and downstream of the gene (chromosome 19, position 44,409,039 to 46,412,650). The PRS for CSF Aβ42 was multiplied by -1 to align a higher risk score with decreased CSF Aβ42 (and increased brain Aβ42 concentration). Scores were rank inverse-normal transformed to place them on the same scale [41] . Individual scores were averaged to generate a composite A/T/N score.
All studies were approved by the institutional review board (IRB) of each participating location. Data sharing was carried out within the guidelines of IRB protocols. PRS performance was measured using p-value significance and adjusted R 2 values to compare the variance explained across PRS and overall models. For mixed effects models, the marginal coefficient of determination is reported as pseudo R 2 . Sensitivity analyses were performed excluding individuals diagnosed with clinical AD or excluding clinically diagnosed AD and MCI participants. Additionally, all PRS were generated including and excluding the APOE region. Sex interactions on all outcomes were also investigated, and if overall interactions were found, sex-stratified analyses were performed.
Results
PRS Validation
The predictive performance of PRS on CSF Aβ42 were compared. Not surprisingly, the CSF Aβ42 PRS was negatively associated with measured CSF Aβ42 levels, indicating a higher CSF Aβ42 PRS is associated with higher brain Aβ42 burden. The CSF Aβ42 PRS model explained 4.6% of the variance in CSF Aβ42 levels (Supplemental Table 2 , p=4.1E-06). The association remained significant after removing the APOE region (p=6.5E-04, R 2 =0.035) and when restricting the sample to cognitively normal and MCI individuals (p=3.7E-05, R 2 =0.045). Notably, the A/T/N score was the best predictor of CSF Aβ42, with the model explaining 7.6% of the variance (Supplemental Figure 1, p=6 .8E-12) and this score was predictive of CSF Aβ42 in normal cognition controls (p=1.1E-03, R 2 =0.076).
CSF Ptau PRS showed a significant positive association with CSF ptau181 concentrations (Supplemental Table 3 , R 2 =0.038, p=0.003), however this association did not meet the Bonferroni threshold for all 40 models tested. This association remained significant after excluding the APOE region (p=0.01, R 2 =0.046) and after exclusion of AD participants (p=1.1E-03, R 2 =0.059). Again, the A/T/N PRS showed the strongest association with CSF ptau181 concentrations compared to other scores, where a higher A/T/N PRS was associated with higher CSF ptau levels (p=8.3E-06, R 2 =0.051).
We also validated the hippocampal volume PRS, whereby a higher PRS for left hippocampal volume was associated with greater left hippocampal volume at baseline and the model explained 22.2% of variance in the LHIPV data (Supplemental Table 4 , p=8.9E-04).
Notably, this association was significant after excluding the APOE region. The PRS for clinical AD (calculated using a subset of the original IGAP data), and CSF Aβ42 PRS were also significantly associated with baseline left hippocampal volume. The clinical AD PRS score showed the strongest association and accounted for the highest variance in this outcome (R 2 =0.223, p=3.0E-04), although all PRS had similar effect sizes (R 2 ranging from 0.215 to 0.223).
As expected, the clinical AD PRS showed the strongest association with AD diagnosis (Supplemental Table 5 , p=7.4E-08, R 2 =0.111) and remained significant after exclusion of the APOE region (p=1.3E-03, R 2 =0.079). The ATN and CSF Aβ42 PRS were also significantly associated with AD diagnosis and remained significant after APOE region exclusion, however the CSF Aβ42 PRS association did not remain significant after Bonferroni correction.
PRS Association with Baseline Cognition
Higher A/T/N PRS and clinical AD PRS were significantly associated with lower baseline executive function in ADNI (Table 2, Supplemental Figure 2 ; A/T/N p=0.004, R 2 =0.115;
Clinical AD p=0.02, R 2 =0.112), and these PRS models accounted for 11.2-11.4% of variability in baseline executive function but did not meet the Bonferroni correction threshold. These associations were not significant after exclusion of the APOE region but remained significant after exclusion of AD participants. It is noteworthy that the CSF Aβ42 PRS model also showed a nominal association with baseline executive function (p=0.04).
The clinical AD and A/T/N PRS were associated with baseline memory performance ( Figure 3 ; A/T/N p=0.048, R 2 =0.093; Clinical AD p=6.8E-05, R 2 =0.102), and remained significant after excluding AD participants from the analysis. However, the associations were not statistically significant when excluding the APOE region and the A/T/N PRS associations did not meet the Bonferroni p-value threshold. LHIPV PRS was also nominally associated with baseline memory (p=0.049, R 2 =0.093).
PRS Performance on Longitudinal Cognition
The A/T/N PRS showed the strongest association with longitudinal executive function, where a higher score was associated with a faster decline in executive function, and this association remained statistically significant when removing the APOE region or excluding AD participants (Table 4, Figure 1 In additional sensitivity analyses, we did not observe any sex interactions with PRS on the baseline or longitudinal cognition outcomes detailed above (Supplemental Table 6 ).
Discussion
We found that the A/T/N PRS with combined genetic risk for CSF ptau181, CSF Aβ42, LHIPV, and clinical AD was a strong predictor of biomarker levels during the preclinical stages of AD, and a better predictor of longitudinal executive function compared to a PRS for late-onset clinical AD. The A/T/N PRS also performed comparably to the clinical AD PRS on baseline cognitive measures (memory, executive function) and longitudinal memory performance.
Together, our findings suggest that utilizing the A/T/N framework by combining genetic risk for AD with genetic risk for AD biomarkers yields a better fitting prediction model, particularly in the earliest stages of disease.
As more GWAS data for AD endophenotypes have become available, it was important that we validate whether PRS for A/T/N are truly predictive of biomarkers in this independent dataset. All PRS were validated for their respective outcomes, and importantly, we found that combining PRS across A/T/N provided a more robust predictor of the individual AD biomarkers.
It could be the case that genetic variants with small effects have functional impact across biomarkers, positioning a composite A/T/N score to capture more genetic overlap between biomarkers and amplify relevant signals for associations. As sample sizes continue to increase in genetic studies of amyloid, tau, and hippocampal atrophy in late-life, it is quite likely that the sensitivity of these PRS will continue to improve. Currently, the scores appear to provide a small boost in sensitivity to early deposition of pathology.
Similarly, the A/T/N PRS appeared to provide more sensitivity to risk of executive function decline, particularly when including participants across the clinical spectrum of AD. In contrast, the clinical AD PRS appeared to perform comparably to the A/T/N score in predicting memory performance, suggesting that the current polygenic predictors of clinical AD may be particularly sensitive to memory dysfunction. Given that many of the cohorts included in the AD GWAS studies come from memory clinics across the country, it is not surprising to see such robust associations with memory performance. However, when the APOE region is excluded the A/T/N score remains significantly associated with memory decline while the clinical AD score does not, suggesting that the A/T/N score may provide genetic prediction above and beyond the APOE region in the context of memory decline. However, the clinical utility of the additional sensitivity provided by the A/T/N PRS in non-memory domains remains to be determined.
It is notable that the associations we observed with biomarkers of neuropathology and longitudinal cognitive decline explained variance above and beyond APOE, which has been a limitation of previous PRS analyses [42] . Certainly, APOE is a critical genetic component in AD, but AD remains a complex polygenic trait including many genetic effects with small effect sizes.
Pooling across these small effects does appear to provide a score that shows more robust associations than reliance on the top genetic signal alone.
Previous work has shown that the clinical AD PRS derived from IGAP summary statistics was predictive of bilateral hippocampal volume in a Brazilian youth cohort [43] , aligning with the clinical AD PRS association with left hippocampal volume demonstrated in this study. Together, these results may suggest that genetic drivers of hippocampal volume are influential throughout life. This association also fits with previous literature which reported a PRS for late-onset AD was associated with hippocampal function, as measured by functional magnetic resonance imaging (fMRI) [44] . Few studies to date have tested PRS associations with late life cognitive change, and results have been mixed [45, 46] .
A strength of our chosen validation set was the wealth of clinical and genetic data including more than 1,100 participants. However, the GWAS summary statistics and the present analyses were sampled from highly-educated, Non-Hispanic White populations and generalizability of findings to more diverse groups is limited. PRS analyses can capture the common genetic risk for disease, however other disease contributors such as rare variants, gene-gene and gene-environment interactions may not be as accurately modeled. Larger sample sizes for GWAS of endophenotypes in particular would improve power of PRS models.
In their current form, PRS models of CSF biomarkers explain a small portion of the variance, suggesting substantial gains could be reached as sample sizes grow.
Overall, this study suggests an integration of genetic components in the A/T/N framework can be used to explain a greater percentage of variability in longitudinal cognition data compared to previously published genetic risk scores for late-onset clinical AD. Importantly, the calculated A/T/N PRS was significantly associated with longitudinal cognition in the absence of the APOE region, suggesting a greater degree of genetic risk for cognitive decline can be captured above and beyond APOE. Future PRS development should employ endophenotypespecific approaches to predict cognitive trajectories. 
